Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

por Gadgeel, S, Peters, S, Mok, T, Shaw, A T, Kim, D W, Ou, S I, Pérol, M, Wrona, A, Novello, S, Rosell, R, Zeaiter, A, Liu, T, Nüesch, E, Balas, B, Camidge, D R
Publicado 2018

Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)

por Bugat, R, Bataillard, A, Lesimple, T, Voigt, J J, Culine, S, Lortholary, A, Merrouche, Y, Ganem, G, Kaminsky, M C, Negrier, S, Perol, M, Laforêt, C, Bedossa, P, Bertrand, G, Coindre, J M, Fizazi, K
Publicado 2003

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

por Hardenberg, M.C., Patel, B., Matthews, C., Califano, R., Garcia Campelo, R., Grohe, C., Hong, M.H., Liu, G., Lu, S., de Marinis, F., Pérol, M., Soo, R.A., Stiles, B.M., Tiseo, M., Tsuboi, M.
Publicado 2022

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

por Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.
Publicado 2021

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year...

por Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.
Publicado 2021

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

por Bonomi, P D, Gandara, D, Hirsch, F R, Kerr, K M, Obasaju, C, Paz-Ares, L, Bellomo, C, Bradley, J D, Bunn Jr, P A, Culligan, M, Jett, J R, Kim, E S, Langer, C J, Natale, R B, Novello, S, Pérol, M, Ramalingam, S S, Reck, M, Reynolds, C H, Smit, E F, Socinski, M A, Spigel, D R, Vansteenkiste, J F, Wakelee, H, Thatcher, N
Publicado 2018

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

por Heudel, P., Chabaud, S., Perol, D., Flechon, A., Fayette, J., Combemale, P., Tredan, O., Desseigne, F., de la Fouchardiere, C., Boyle, H., Perol, M., Bachelot, T., Cassier, P., Avrillon, V., Terret, C., Michallet, A.-S., Neidhardt-Berard, E.-M., Nicolas-Virelizier, E., Dufresne, A., Belhabri, A., Brahmi, M., Lebras, L., Nicolini, F., Sarabi, M., Rey, P., Bonneville-Levard, A., Rochefort, P., Provensal, A.-M., Eberst, L., Assaad, S., Swalduz, A., Saintigny, P., Toussaint, P., Guillermin, Y., Castets, M., Coutzac, C., Meeus, P., Dupré, A., Durand, T., Crochet, H., Fervers, B., Gomez, F., Rivoire, M., Gregoire, V., Claude, L., Chassagne-Clement, C., Pilleul, F., Mognetti, T., Russias, B., Soubirou, J.-L., Lasset, C., Chvetzoff, G., Mehlen, P., Beaupère, S., Zrounba, P., Ray-Coquard, I., Blay, J.-Y.
Publicado 2021